Incyte Corp DEFA14A, filed May 14, 2020
Incyte Corp (INCY)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14A
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
|
Filed by the Registrant x | |
|
Filed by a Party other than the Registrant o | |
|
Check the appropriate box: | |
|
o |
Preliminary Proxy Statement |
|
o |
Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
|
o |
Definitive Proxy Statement |
|
x |
Definitive Additional Materials |
|
o |
Soliciting Material under §240.14a-12 |
|
INCYTE CORPORATION | ||
|
| ||
|
| ||
|
Payment of Filing Fee (Check the appropriate box): | ||
|
x |
No fee required. | |
|
o |
Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. | |
|
|
(1) |
Title of each class of securities to which transaction applies: |
|
|
(2) |
Aggregate number of securities to which transaction applies: |
|
|
(3) |
Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
|
|
(4) |
Proposed maximum aggregate value of transaction: |
|
|
(5) |
Total fee paid: |
|
o |
Fee paid previously with preliminary materials. | |
|
o |
Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. | |
|
|
(1) |
Amount Previously Paid: |
|
|
(2) |
Form, Schedule or Registration Statement No.: |
|
|
(3) |
Filing Party: |
|
|
(4) |
Date Filed: |
Incyte Corporation
1801 Augustine Cut-Off
Wilmington, Delaware 19803
Supplement to Proxy Statement
for Annual Meeting of Stockholders
Tuesday, May 26, 2020
1:00 PM Eastern Daylight Time
1815 Augustine Cut-Off, Wilmington, Delaware 19803
This supplement, dated May 14, 2020, supplements the definitive proxy statement (the “Proxy Statement”) of Incyte Corporation (the “Company” or “Incyte”) filed with the Securities and Exchange Commission on April 24, 2020, relating to the Company’s Annual Meeting of Stockholders to be held on May 26, 2020 (the “2020 Annual Meeting”).
Corporate Governance Update
Departing Director
On May 13, 2020, Paul A. Friedman, M.D. notified the Company that, should he be re-elected as a member of the Company’s Board of Directors (the “Board”), at the Company’s 2020 Annual Meeting, he will serve on the Board until the Company’s 2021 Annual Meeting of Stockholders (the “2021 Annual Meeting”) and will retire from the Board effective at the time of the Company’s 2021 Annual Meeting of Stockholders. Dr. Friedman has been a member of our Board since 2001.
Changes to Nominating and Corporate Governance Composition
Effective May 13, 2020, Dr. Friedman has resigned from the Nominating and Corporate Governance Committee. Our Board has added Jean-Jacques Bienaimé to the Nominating and Corporate Governance Committee.
New Science and Technology Committee of the Board of Directors
Our Board has created a new Science and Technology Committee (the “Science Committee”). Our Board has appointed Dr. Friedman as Chair of this Science Committee because of Dr. Friedman’s extensive expertise in drug development and discovery, including medicinal chemistry and biology, as well as his deep understanding of Incyte and our research and development organization. Accordingly, our Board believes that, even with this limited time on the Science Committee, Dr. Friedman will provide the foundational expertise to assure the long term viability and value of the Science Committee. Consequently, our Board believes it is in the best interests of our stockholders that Dr. Friedman lead the new Science Committee in its oversight of our research and development operations and strategy as we seek to continue the scientific excellence at Incyte that has so far led to the discovery of four approved medicines around the world.
Our Board has also appointed Edmund P. Harrigan, M.D. and Katherine A. High, M.D. to the Science Committee.